Connie P Duong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6734656/publications.pdf

Version: 2024-02-01

24 papers	9,183 citations	393982 19 h-index	580395 25 g-index
26 all docs	26 docs citations	26 times ranked	12420 citing authors

#	Article	IF	Citations
1	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	6.0	3,689
2	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015, 350, 1079-1084.	6.0	2,539
3	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	6.6	645
4	Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical Cancer Research, 2013, 19, 5636-5646.	3.2	598
5	Cross-reactivity between tumor MHC class Iâ€“restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	6.0	217
6	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	15.2	216
7	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. European Urology, 2020, 78, 195-206.	0.9	192
8	Autoimmunity associated with immunotherapy of cancer. Blood, 2011, 118, 499-509.	0.6	163
9	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
10	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nature Medicine, 2020, 26, 919-931.	15.2	118
11	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. Molecular Therapy, 2014, 22, 18-27.	3.7	112
12	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Molecular Immunology, 2015, 67, 46-57.	1.0	100
13	Oncolytic Virus and Antiâ€“4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research, 2012, 72, 1651-1660.	0.4	94
14	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. Frontiers in Immunology, 2018, 9, 2480.	2.2	57
15	Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity. Cancer Research, 2010, 70, 9591-9598.	0.4	49
16	Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy, 2011, 3, 33-48.	1.0	44
17	Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach. PLoS ONE, 2013, 8, e63037.	1.1	44
18	Cancer Induces a Stress Ileopathy Depending on Î²-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discovery, 2022, 12, 1128-1151.	7.7	44

#	Article	IF	Citations
19	Foxp3 Expression in Macrophages Associated with RENCA Tumors in Mice. PLoS ONE, 2014, 9, e108670.	1.1	23
20	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. OncoImmunology, 2017, 6, e1299303.	2.1	20
21	Enhancing adoptive immunotherapy of cancer. Expert Opinion on Biological Therapy, 2010, 10, 531-545.	1.4	14
22	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.4	14
23	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. OncoImmunology, 2014, 3, e963395.	2.1	8
24	Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. Immunotherapy, 2013, 5, 577-590.	1.0	5